Difference between revisions of "Ruxolitinib (Jakafi)"
m (Text replace - "package insert<ref name="insert"></ref>." to "prescribing information.<ref name="insert"></ref>") |
|||
| Line 10: | Line 10: | ||
==Patient drug information== | ==Patient drug information== | ||
*[http://www.incyte.com/products/uspi_jakafi.pdf#page=20 Ruxolitinib (Jakafi) package insert PDF pages 20-22]<ref name="insert"></ref> | *[http://www.incyte.com/products/uspi_jakafi.pdf#page=20 Ruxolitinib (Jakafi) package insert PDF pages 20-22]<ref name="insert"></ref> | ||
| + | |||
| + | ==History of changes in FDA indication== | ||
| + | * 11/16/2011: Initial FDA approval | ||
==References== | ==References== | ||
<references/> | <references/> | ||
Revision as of 15:36, 6 June 2013
Also formerly known as INCB018424.
General information
Class/mechanism: Kinase inhibitor of Janus Associated Kinases (JAKs) JAK1 and JAK2. Modulates gene expression by interfering with the JAK signaling pathway, which involves recruitment, activation, and localization of STATs (signal transducers and activators of transcription) to cytokine receptors and the nucleus.[1][2]
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Patient drug information
History of changes in FDA indication
- 11/16/2011: Initial FDA approval